Basecamp Wealth Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Basecamp Wealth Advisors's NVS Position: Q3 2026 in Review
Basecamp Wealth Advisors reduced its Novartis (NVS) stake by 32% in Q3 2026, selling an estimated $526K and leaving 7,494 shares worth $1.07M. The position accounts for 0.24% of the portfolio, ranked #38.
Basecamp Wealth Advisors first reported a position in NVS in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.72M in Q2 2026. 1,543 funds tracked by Wall St. Rank hold NVS as of Q3 2026.
- Basecamp Wealth Advisors held 7,494 shares of Novartis worth $1.07M as of Q3 2026.
- Basecamp Wealth Advisors sold 3,465 Novartis shares in Q3 2026, an estimated $526K.
- Novartis made up 0.24% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #38 holding.
- Basecamp Wealth Advisors first reported a position in Novartis in Q4 2025 and has held it in 4 quarters since.
- Basecamp Wealth Advisors's Novartis position peaked at $1.72M in Q2 2026.
- 1,543 funds tracked by Wall St. Rank held Novartis as of Q3 2026.
Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.